Shedding of CD18 from RA SFMC and PBMC was increased by adding recombinant human TNFα and decreased by neutralizing TNFα with adalimumab (all P<0.05) (Fig 3A and 3B). Here, ITGB2 is linked to rheumatoid arthritis.